This test is most useful if any of these apply to you.
NT-proBNP can rise before heart failure causes symptoms. In large studies following adults without heart failure at the start, higher blood levels predicted more heart failure, strokes, and cardiovascular deaths over subsequent years. The association remained after accounting for standard risk factors.
This is an established clinical marker for evaluating possible heart failure and assessing prognosis after diagnosis. Its use for prevention is more selective: guidelines support screening people at increased risk when the result leads to appropriate evaluation and follow-up care. The benefit of routinely screening healthy adults at low risk hasn't been established.
Heart muscle cells make a larger protein called proBNP, especially when the heart's walls are stretched. Processing this protein produces BNP and NT-proBNP. BNP is an active hormone that helps blood vessels relax and the kidneys release salt and water. NT-proBNP has no established hormone activity.
NT-proBNP remains in the circulation longer than BNP. Its concentration reflects how much is produced and released, how the parent protein is processed, and how quickly the fragment is removed. Kidney function affects that removal, so the number is an indirect measure of heart strain.
Pressure or fluid overload can come from a weakened heart, impaired filling, valve disease, or an abnormal rhythm. The test reports the blood concentration in pg/mL. It doesn't identify which of these problems is responsible.
Heart failure can involve weak pumping, difficulty filling, or both. Ejection fraction is the proportion of blood the main pumping chamber ejects with each beat. Heart failure with reduced ejection fraction involves reduced pumping strength. Heart failure with preserved ejection fraction can involve high filling pressures despite a preserved proportion being pumped out.
In a pooled analysis of 41,427 adults from nine cohorts followed for about 11 years, each doubling of NT-proBNP was associated with about 47% higher risk of developing heart failure. Adding it to standard risk factors improved prediction. That establishes useful risk information, though it doesn't by itself prove that testing everyone improves health.
The marker also predicts outcomes in established heart failure. Among 3,480 participants with preserved ejection fraction in the I-PRESERVE trial, those above the group's median NT-proBNP had about 80% higher risk of death or cardiovascular hospitalization than those below it.
In an analysis of people with reduced ejection fraction, reaching the study's lower NT-proBNP target during treatment was associated with about three-quarters lower risk of subsequent heart failure hospitalization or cardiovascular death. This was a comparison between treatment responders and nonresponders, so the difference cannot be attributed entirely to lowering the marker.
A meta-analysis of 11 general-population studies involving 25,715 adults found that people in the highest NT-proBNP categories had about 2.4 times the risk of dying from any cause compared with those in the lowest categories. The corresponding risks were about 3.8 times higher for cardiovascular death and 2.35 times higher for coronary heart disease death. The categories and follow-up periods differed between studies.
A nationally representative study of 10,645 US adults followed for a median of 17.3 years also linked higher NT-proBNP to cardiovascular and all-cause death.
In the ARIC study, adults without diagnosed cardiovascular disease in the highest NT-proBNP category had long-term cardiovascular risk comparable to or greater than adults with established cardiovascular disease. That finding concerned a selected high-level group. It doesn't establish that every mildly raised result carries the same risk as a known heart condition.
Higher NT-proBNP is associated with stroke, especially strokes caused by clots that form in the heart and travel to the brain. These are called cardioembolic strokes. Atrial fibrillation can contribute to both higher NT-proBNP and this type of stroke. It is an irregular heart rhythm that increases the chance of blood clots forming in the heart.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| About 1,500 participants selected from the REGARDS cohort, with about 5 years of follow-up | Highest quarter of NT-proBNP versus lowest quarter | About 2.9 times the risk of ischemic stroke and about 9 times the risk of cardioembolic stroke; the latter estimate was imprecise |
| 10,902 ARIC participants followed for about 11 years | Both NT-proBNP and troponin T high versus neither high | About 2.7 times the risk of any stroke and about 6.3 times the risk of cardioembolic stroke |
| 58,173 adults from six European cohorts followed for about 8 years | Highest quarter of NT-proBNP versus lowest quarter | Higher stroke risk, with most recorded strokes caused by blocked blood vessels |
These findings support NT-proBNP as a risk marker. They don't establish it as a stand-alone stroke screening test or a basis for prescribing blood thinners. The ARIC comparison also included troponin T, so its effect size cannot be attributed to NT-proBNP alone.
NT-proBNP often rises as kidney function falls. Reduced removal contributes, but kidney disease can also increase blood pressure and fluid retention, adding real strain on the heart. Higher NT-proBNP remains associated with mortality across kidney-function groups, so a raised result shouldn't automatically be dismissed as reduced clearance.
In a study of 23,860 people with chronic kidney disease and no heart failure, higher NT-proBNP was associated with faster kidney disease progression in the early and middle stages. This was observational evidence. It doesn't establish NT-proBNP as a replacement for measurements of kidney filtration or urine albumin.
The same concentration doesn't carry the same meaning for everyone. Levels generally rise with older age and are higher in women than men during adulthood. National US data also found differences between self-identified racial and ethnic groups.
In the Multi-Ethnic Study of Atherosclerosis, which included 5,597 adults without clinical cardiovascular disease, adjusted NT-proBNP levels were 44% lower in Black participants and 46% lower in Chinese participants than in White participants. These are group averages with substantial overlap between individuals.
Other community research found that the absolute risk associated with a given NT-proBNP concentration differed by sex and racial group. A lower average concentration in a group doesn't establish lower heart failure risk. These findings support considering the rest of your risk profile; they don't provide a validated race-based correction for your individual result.
Obesity also tends to lower NT-proBNP, including in people with heart failure. The explanation is incomplete and appears to involve changes in peptide production and processing. Increased removal of BNP by fat tissue cannot fully explain the finding because NT-proBNP isn't removed through the same peptide-clearance receptor.
This matters most when evaluating persistent breathlessness. A substantial minority of people with heart failure with preserved ejection fraction have low NT-proBNP, particularly when they have obesity. Studies using pressure measurements during exercise have confirmed heart failure in people whose blood result and resting evaluation were reassuring.
The 2022 American heart failure guideline says natriuretic peptide screening can be useful in people at risk when followed by team-based care. The American Diabetes Association's 2026 Standards of Care recommend considering BNP or NT-proBNP screening in adults with diabetes and using echocardiography to evaluate abnormal findings.
The STOP-HF randomized trial tested a screening and collaborative-care program using BNP, a related but different blood measurement. The program reduced the combined outcome of new heart dysfunction or heart failure and reduced emergency cardiovascular hospitalizations. Heart failure alone was uncommon, and the difference in that outcome wasn't statistically reliable.
PONTIAC used NT-proBNP itself to select 300 adults with type 2 diabetes and no known cardiac disease. Participants assigned to intensified specialist care had fewer cardiac hospitalizations or cardiac deaths over two years. This supports a linked testing-and-care strategy in a selected population.
Screening can also lead to additional scans and appointments when the blood result doesn't correspond to heart failure. The trials studied people with risk factors, and their benefits came from the care that followed testing. They don't establish a benefit from measuring NT-proBNP without a plan for interpreting and acting on the result.
A raised result can reflect an acute problem as well as chronic heart disease. Sepsis, severe pneumonia, a pulmonary embolism, and surgery can raise NT-proBNP. A pulmonary embolism is a blood clot in the lungs. These increases may represent temporary heart stress and changes in clearance, so they aren't automatically laboratory errors.
Sacubitril-valsartan affects BNP and NT-proBNP differently. It blocks neprilysin, an enzyme that breaks down BNP. BNP may therefore rise early in treatment, while NT-proBNP isn't directly affected by blocked breakdown through that enzyme. NT-proBNP is often easier to interpret during treatment initiation, but BNP still carries useful prognostic information.
Major weight loss can change the relationship between this number and heart health. Studies of bariatric surgery found that NT-proBNP could rise despite improvements in heart structure or filling. A higher result after substantial weight loss therefore needs context, and a lower number isn't an unconditional measure of better health.
Repeated measurements can add information to a single result. In a long-running community study, changes between visits were associated with later heart failure hospitalization and death. In established heart failure, falling levels often accompany improvement and lower subsequent risk.
There is still meaningful fluctuation within the same person. Studies of stable heart failure and dialysis populations have reported different amounts of natural variability. No single percentage change reliably distinguishes improvement or deterioration in every setting, and trends remain affected by kidney function, heart rhythm, illness, and weight.
A useful prognostic marker isn't automatically a treatment target. In GUIDE-IT, adjusting heart failure treatment to reach an NT-proBNP target did not improve hospitalization or cardiovascular mortality compared with well-managed usual care. The result belongs alongside symptoms, examination findings, imaging, and the treatments already proven to help.
Evidence-backed interventions that affect your NT-proBNP level
NT-proBNP is best interpreted alongside these tests.